Phase I dose-escalation study of desynchronized irinotecan plus bevacizumab, oxaliplatin, 5-fluorouracil, and folinic acid (bFOLFIRINOX-3) administration in chemorefractory metastatic colorectal cancer patients.

Jean David Fumet,Alice Hervieu,Audrey Hennequin,Sylvie Zanetta,Aurélie Bertaut,François Ghiringhelli

Phase I dose-escalation study of desynchronized irinotecan plus bevacizumab, oxaliplatin, 5-fluorouracil, and folinic acid (bFOLFIRINOX-3) administration in chemorefractory metastatic colorectal cancer patients.

2021

Jean David Fumet
Alice Hervieu
Audrey Hennequin
Sylvie Zanetta
Aurélie Bertaut
François Ghiringhelli

e15573Background: Treatment of non-resectable metastatic colorectal cancer (mCRC) involves chemotherapy based on 5-fluorouracil, oxaliplatin and irinotecan and monoclonal antibodies targeting VEGF ...

Keywords:

Folinic acid
Medicine
Oxaliplatin
Internal medicine
Fluorouracil
Bevacizumab/oxaliplatin
Oncology
Colorectal cancer
Chemotherapy
Irinotecan
Monoclonal antibody

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations